Revised Intimation for Cessation of Independent Directors on completion of their Tenure.
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has informed BSE that two Independent Directors, Mr. Pankaj Takkar (DIN: 07414345) and Mr. Ravi Shanker Singh (DIN: 02303588), ceased office on January 31, 2026 after completing their second term as Independent Directors. This is a revised intimation because BSE flagged that the original disclosure was not made within 24 hours — the company filed it on February 2, 2026 citing procedural delays and internal verifications. The company has stated there is no financial or operational impact and no prejudice to shareholder interests. Board committees have been reconstituted with existing Independent Directors (Mr. Bhavesh Mahajan, Mr. Vinod Kumar Sharma, Mr. PreetMohinder Singh Bedi) stepping in.
Routine end-of-tenure event with no operational or financial impact stated. However, the delayed disclosure (beyond SEBI's 24-hour requirement) and the need for a revised intimation may raise minor corporate governance concerns among investors.